Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsMVP Health Care Infliximab Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentMVP Health CarePolicy N/A

    Medicare Part B: Infliximab

    Customize your policy alerts

    Sign up for all MVP Health Care policy alerts

    Know when MVP Health Care releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and medical-necessity criteria for infliximab and specified infliximab biosimilars billed under the Medicare Part B medical benefit, including initial and continued treatment for covered inflammatory and immune-mediated conditions.

    Policy Summary
    PayerMVP Health Care
    PolicyMedicare Part B: Infliximab
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJan 1, 2026
    Next Review DateN/A
    Key ActionSubmit documentation showing that infliximab is ordered by or prescribed in consultation with an appropriate specialist.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    4Products requiring prior authorization
    6 monthsInitial approval period
    12 monthsMaximum continuation period
    2 dosesCheckpoint inhibitor-related colitis limit

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    4
    Specialist types identified

    Coverage Criteria

    General Requirements

    Covered for all indications when ALL of the following requirements are met:

    ALL of the following

    • Therapy is ordered by or provided in consultation with an appropriate specialist: rheumatologist, immunologist, dermatologist, gastroenterologist, or colorectal surgeon.
    • Initial approval is for 6 months.
    • Continuation approval may be granted for up to 12 months when documentation demonstrates improved member status.

    Initial Therapy — Ankylosing Spondylitis

    Covered for active moderate to severe ankylosing spondylitis when ALL of the following are met:

    ALL of the following

    • Chart notes document failure of at least one trial of an NSAID at the maximum tolerated dose, unless the member has a contraindication to NSAID therapy, such as cardiovascular disease, peptic ulcer disease, or renal disease.
    • Chart notes document significant clinical symptoms, such as fatigue, spinal pain, arthralgia, inflammation of joints and tendons, and morning stiffness.
    • For patients with symptomatic peripheral arthritis, chart notes document an insufficient response to at least one local corticosteroid injection.

    Initial Therapy — Crohn's Disease

    Covered for active moderate to severe Crohn's disease confirmed by endoscopy, or by capsule endoscopy when appropriate, when the applicable requirements below are met:

    ALL of the following

    • Active moderate to severe Crohn's disease is confirmed by endoscopy, or by capsule endoscopy when appropriate.
    • ONE of the following

      • The member is younger than 18 years; pediatric Crohn's disease requests will be reviewed on a case-by-case basis.
      • Documentation demonstrates failure or inadequate response to a 12-week trial of adalimumab.
      • Documentation provides a rationale explaining why the member or caregiver is unable to self-administer adalimumab.

    Initial Therapy — Psoriatic Arthritis

    Covered for moderate to severe active psoriatic arthritis when ALL of the following applicable requirements are met:

    ALL of the following

    • The member has moderate to severe psoriatic arthritis, indicated by at least 3 tender joints and at least 3 swollen joints on 2 separate occasions at least 1 month apart.
    • Chart notes document use of at least one NSAID at the maximum tolerated dose, unless the member has a contraindication to NSAID therapy, such as cardiovascular disease, peptic ulcer disease, or renal disease.
    • ONE of the following

      • Chart notes document failure to respond to an adequate trial of at least 3 months, including 2 months at the standard target dose, of at least one DMARD: leflunomide, sulfasalazine, or methotrexate.
      • The member has pure axial manifestations; a trial of a nonbiologic DMARD is not required.

    Initial Therapy — Rheumatoid Arthritis

    Covered for active moderate to severe adult rheumatoid arthritis when ALL of the following applicable requirements are met:

    ALL of the following

    • The member has active moderate to severe adult rheumatoid arthritis, defined by persistent or recurrent symptoms with documented synovitis and morning stiffness of significant duration that inhibits activities of daily living.
    • ONE of the following DMARD-history pathways

      • ALL of the following

        • Chart notes document failure to respond to one or more nonbiologic DMARDs, including a 3-month trial of methotrexate at the maximally tolerated dose.
        • Failure is demonstrated by the provider's assessment documenting no improvement in joint counts and/or physical symptoms and inflammatory markers while on therapy.
      • ALL of the following

    Initial Therapy — Ulcerative Colitis

    Covered for active moderate to severe ulcerative colitis when ALL of the following applicable requirements are met:

    ALL of the following

    • Chart notes document an inadequate response to or intolerance of conventional therapy, including anti-inflammatory aminosalicylates such as mesalamine (5-ASA) or sulfasalazine, 6-mercaptopurine, and azathioprine.
    • ONE of the following additional conditions

      • If conventional therapy is not appropriate, documentation provides rationale for the medical necessity of infliximab, such as a contraindication or disease severity; the request will be reviewed case-by-case in accordance with current American College of Gastroenterology guidelines.
      • The request is for pediatric ulcerative colitis and will be reviewed case-by-case in accordance with current American College of Gastroenterology guidelines.

    Refractory Granulomatosis With Polyangiitis

    Covered case-by-case when the following criterion is met:

    ALL of the following

    • The request is for refractory granulomatosis with polyangiitis (Wegener's granulomatosis), and infliximab is used in combination with corticosteroids.

    Immune Checkpoint Inhibitor-Related Diarrhea or Colitis

    Covered only for the limited acute course when ALL of the following are met:

    ALL of the following

    • The member has been receiving an immune checkpoint inhibitor, such as nivolumab, pembrolizumab, atezolizumab, avelumab, durvalumab, or cemiplimab.
    • The member has moderate (grade 2) to severe (grade 3–4) diarrhea or colitis related to immunotherapy.
    • Coverage is limited to infliximab 5 mg/kg, up to a maximum of 2 doses within 1 month.

    Infliximab is not considered medically necessary when the indication, age, dose, frequency of dosing, or duration of therapy is outside FDA-approved package labeling.

    Continuation of infliximab for immune checkpoint inhibitor-related diarrhea or colitis is not a covered benefit.

    Infliximab is not considered medically necessary for members with a known hypersensitivity to murine proteins, heart failure (NYHA class III or IV) when dosed above 5 mg/kg, or use in combination with TNF blockers, other biologics, or an interleukin-1 inhibitor.

    Initial Therapy

    Initial therapy

    Initial approval requires the general specialist requirement and the applicable diagnosis-specific criteria.

    Initial authorization

    • The request is for a covered indication and meets the applicable diagnosis-specific medical-necessity criteria.
    • Infliximab is ordered by or provided in consultation with an appropriate rheumatologist, immunologist, dermatologist, gastroenterologist, or colorectal surgeon.
    • Initial approval is limited to 6 months.6 months

    Continuation Therapy

    Continuation approval

    Continuation may be authorized when the member has improved or continues to benefit from treatment.

    Continuation therapy

    • Documentation shows improved member status or continued clinical benefit from infliximab.
    • Continuation approval may extend up to 12 months.Up to 12 months
    • If infliximab has not produced the full desired effect or is considered a clinical failure, clinical rationale for continuing treatment is provided.

    Continuation exclusion

    Continuation is not covered for this indication.

    Checkpoint inhibitor-related colitis limitation

    Coding and Clinical Thresholds

    Codes Requiring Prior Authorization (covered under the medical benefit)HCPCSCovered
    J1745Injection, infliximab, 10 mg (Remicade / Infliximab)
    Q5103Injection, infliximab, 10mg (Inflectra)
    Q5104Injection, infliximab, 10mg (Renflexis)
    Q5121Infliximab, 10mg (Avsola)
    Plaque psoriasis body surface area
    Standard thresholdAt least 10% of the body surface area (BSA) is affected.
    Alternative thresholdAt least 3% BSA is affected with qualifying prior-treatment failure or intolerance.
    Qualifying prior treatmentInadequate response or intolerance to phototherapy, methotrexate, cyclosporine, or acitretin.
    Psoriatic arthritis joint involvement
    Tender jointsAt least 3 tender joints.
    Swollen jointsAt least 3 swollen joints.
    Confirmation requirement

    Provider Requirements and Authorization Actions

    Prior Authorization

    Prior Authorization Required for Part B Codes

    Prior authorization is required for infliximab products billed under the medical benefit using the listed Part B codes.

    • J1745 — Infliximab (Remicade/Infliximab), 10 mg
    • Q5103 — Inflectra, 10 mg
    • Q5104 — Renflexis, 10 mg
    • Q5121 — Avsola, 10 mg
    Prior Authorization

    Authorization Periods

    Request an initial authorization for six months. Continuation may be authorized for up to one year when documentation shows improved member status and continued benefit.

    • Initial approval: 6 months
    • Continuation: up to 12 months with documented improvement and benefit

    Clinical Background

    Infliximab and its listed biosimilars bind tumor necrosis factor alpha (TNF-alpha), a pro-inflammatory cytokine involved in initiating and maintaining tissue inflammation. By inhibiting TNF-alpha binding to its receptors, these therapies reduce the release of pro-inflammatory cytokines.

    Definitions

    BSA
    AbbreviationBSA.
    DefinitionBody surface area affected by plaque psoriasis.
    Policy thresholdsCoverage pathways include at least 10% BSA, or at least 3% BSA with qualifying prior-treatment failure or intolerance.
    DMARD
    AbbreviationDMARD.
    Full termDisease-modifying antirheumatic drug.
    Examples in this policyLeflunomide, sulfasalazine, and methotrexate.

    Required Prior Therapies

    StepConditionRequired therapyDuration and exceptions
    1Active moderate to severe Crohn’s diseaseTrial of adalimumab with failure or inadequate response12 weeks. The requirement may be satisfied by documenting why the member or caregiver cannot self-administer adalimumab. If adalimumab is medically inappropriate, submit medical-necessity rationale and supporting documentation for case-by-case review.
    StepConditionRequired therapyDuration and exceptions
    1Moderate to severe active psoriatic arthritisAt least one of the following DMARDs: leflunomide, sulfasalazine, or methotrexateAt least 3 months, including 2 months at the standard target dose. Members with pure axial manifestations do not require a nonbiologic DMARD trial. If methotrexate is inappropriate because of alcohol use and the other options are not clinically appropriate, document counseling to abstain from alcohol and the member’s unwillingness to abstain.
    StepConditionRequired therapyDuration and exceptions
    1Active moderate to severe adult rheumatoid arthritisMethotrexate when appropriate, plus at least one other nonbiologic DMARDMethotrexate trial for 3 months at the maximally tolerated dose when appropriate; the other nonbiologic DMARD must be used at a maximally tolerated dose for at least 3 months. Combination with methotrexate is required unless there is acute, aggressive, very rapidly progressive intense inflammatory symmetrical arthritis or significant methotrexate intolerance or contraindication.
    StepConditionRequired therapyDuration and exceptions
    1Active moderate to severe ulcerative colitisConventional therapy, including anti-inflammatory aminosalicylates such as mesalamine or sulfasalazine, 6-mercaptopurine, and azathioprineDocument inadequate response or intolerance. If conventional therapy is not appropriate, submit medical-necessity rationale and supporting documentation for case-by-case review. Pediatric requests are also reviewed case by case.

    Quantity Limits

    Infliximab
    Dose per administration5 mg/kg per dose.
    Maximum number of doses2 doses.
    Time limitDoses must be administered within 1 month.
    ContinuationContinuation therapy is not a covered benefit for immune checkpoint inhibitor-related diarrhea or colitis.
    Policy Summary
    PayerMVP Health Care
    PolicyMedicare Part B: Infliximab
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJan 1, 2026
    Next Review DateN/A
    Key ActionSubmit documentation showing that infliximab is ordered by or prescribed in consultation with an appropriate specialist.
    SourceLink
    On This Page
    Coverage CriteriaInitial TherapyContinuation TherapyCoding and Clinical ThresholdsProvider Requirements and Authorization ActionsClinical BackgroundDefinitionsRequired Prior TherapiesQuantity Limits
    If adalimumab is not appropriate, documentation provides rationale for the medical necessity of infliximab, such as a contraindication or disease severity; the request will be reviewed case-by-case in accordance with current American College of Gastroenterology guidelines.
  1. ALL of the following

    • A methotrexate trial is not appropriate because of alcohol use, and both leflunomide and sulfasalazine are not clinically appropriate.
    • Chart notes document that the member was counseled to abstain from alcohol while taking methotrexate and is unwilling to abstain.
    • The member has a contraindication or significant intolerance to methotrexate.
    • Chart notes document failure to respond to at least one other nonbiologic DMARD at a maximally tolerated dose for at least 3 months.
    • Documentation confirms why methotrexate cannot be used. If methotrexate is not appropriate because of alcohol use, chart notes document counseling to abstain from alcohol while taking methotrexate and the member's unwillingness to abstain.
  2. ONE of the following methotrexate-use conditions

    • Infliximab is given in combination with methotrexate.
    • The member has acute, aggressive, very rapidly progressive, intense inflammatory symmetrical arthritis as defined by the rheumatologist.
    • The member has a significant intolerance or contraindication to methotrexate.
    • Continuation therapy after the limited acute course for immune checkpoint inhibitor-related diarrhea or colitis is not a covered benefit.
    • The covered course is limited to infliximab 5 mg/kg, with a maximum of 2 doses within 1 month.5 mg/kg; maximum 2 doses within 1 month
    Findings must be documented on 2 separate occasions at least 1 month apart.
    Psoriatic arthritis DMARD trial
    Required medication trialAt least one of leflunomide, sulfasalazine, or methotrexate.
    Minimum trial durationAt least 3 months.
    Standard target doseThe trial must include 2 months at the standard target dose.
    Rheumatoid arthritis methotrexate and DMARD trials
    Methotrexate trialThree months at the maximally tolerated dose when appropriate.
    Additional DMARD trialAt least one other nonbiologic DMARD at a maximally tolerated dose for at least 3 months.
    Documented failureFailure is demonstrated by no improvement in joint counts, physical symptoms, and/or inflammatory markers while on therapy.
    Checkpoint inhibitor-related diarrhea or colitis dosing
    IndicationModerate grade 2 to severe grade 3-4 diarrhea or colitis related to immune checkpoint inhibitor therapy.
    DoseInfliximab 5 mg/kg.
    Maximum courseUp to a maximum of 2 doses within 1 month.
    Step Therapy

    Document the Adalimumab Prerequisite for Crohn’s Disease

    For active moderate-to-severe Crohn’s disease confirmed by endoscopy, document the required adalimumab prerequisite or why self-administered adalimumab is not feasible. If adalimumab is not appropriate, provide a case-specific medical-necessity rationale for infliximab consistent with current ACG guidelines.

    • Document failure or inadequate response to a 12-week trial of adalimumab, or provide documentation explaining why the member or caregiver cannot self-administer it.
    • Pediatric Crohn’s disease requests are reviewed case by case.
    • If adalimumab is inappropriate, document the reason, such as contraindication or disease severity.
    Step Therapy

    Document Qualifying Prior Treatment for Plaque Psoriasis

    For active plaque psoriasis, document moderate-to-severe chronic disease and qualifying affected areas or body-surface-area involvement. When BSA is at least 3% but less than 10% and no crucial area is involved, also document inadequate response or intolerance to qualifying prior treatment.

    • The medication must be ordered by or in consultation with a dermatologist.
    • Document involvement of crucial areas such as hands, feet, face, neck, scalp, genitals/groin, or intertriginous areas; BSA ≥10%; or BSA ≥3% with prior-treatment failure/intolerance.
    • Qualifying prior treatment includes phototherapy (UVB or PUVA), methotrexate, cyclosporine, or acitretin.
    Step Therapy

    Document an Adequate DMARD Trial for Psoriatic Arthritis

    For moderate-to-severe active psoriatic arthritis, document failure of an adequate nonbiologic DMARD trial unless the member has pure axial manifestations or an applicable exception.

    • Document at least a 3-month trial, including 2 months at the standard target dose, of leflunomide, sulfasalazine, or methotrexate.
    • Pure axial manifestations do not require a nonbiologic DMARD trial.
    • If methotrexate is not appropriate because of alcohol use and the alternatives are clinically inappropriate, document counseling and the member’s unwillingness to abstain.
    Step Therapy

    Document Nonbiologic DMARD Failure for Rheumatoid Arthritis

    For active moderate-to-severe adult rheumatoid arthritis, document failure of nonbiologic DMARD therapy, including a three-month trial of maximally tolerated methotrexate when appropriate.

    • Document failure of one or more nonbiologic DMARDs, with one including 3 months of maximally tolerated methotrexate.
    • If methotrexate is contraindicated or not tolerated, document failure of another nonbiologic DMARD at a maximally tolerated dose for at least 3 months and why methotrexate cannot be used.
    • Document combination with methotrexate unless the rheumatologist identifies an applicable aggressive-disease exception or methotrexate contraindication/intolerance.
    Step Therapy

    Document Conventional-Therapy Failure for Ulcerative Colitis

    For active moderate-to-severe ulcerative colitis, submit chart notes documenting inadequate response to or intolerance of conventional therapy. If conventional therapy is inappropriate, provide a case-specific rationale for infliximab consistent with current ACG guidelines.

    • Conventional therapies include anti-inflammatory aminosalicylates such as mesalamine (5-ASA) or sulfasalazine, 6-mercaptopurine, and azathioprine.
    • Pediatric ulcerative colitis requests are reviewed case by case.

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: documentation

    Denial Risk

    Exclusions and Non-Covered Use

    Infiximab is not medically necessary when the indication, age, dose, dosing frequency, or duration falls outside FDA-approved package labeling, or when specified safety and combination-therapy exclusions apply.

    • Known hypersensitivity to murine proteins.
    • Heart failure (NYHA class III/IV) at doses greater than 5 mg/kg.
    • Combination with TNF blockers, other biologics, or an interleukin-1 inhibitor.
    Denial Risk

    No Continuation for Checkpoint Inhibitor-Related Colitis

    For immune checkpoint inhibitor-related diarrhea or colitis, continuation of infliximab is not a covered benefit after the limited acute approval.

    • The member must have received an immune checkpoint inhibitor and have moderate (grade 2) to severe (grade 3-4) related diarrhea or colitis.
    • Coverage is limited to infliximab 5 mg/kg, up to a maximum of 2 doses within 1 month.
    • No continuation approval is available for this indication.
    Denial Risk

    Insufficient Response Requires Additional Rationale

    Continuation may be denied, or additional clinical rationale may be required, when infliximab has not produced the full desired effect or is considered a clinical failure.

    • Submit updated clinical findings demonstrating continued benefit.
    • When response is incomplete, explain the anticipated benefit and medical necessity of continuing treatment.
    Immune checkpoint inhibitor-related diarrhea or colitis
    CauseDiarrhea or colitis caused by treatment with an immune checkpoint inhibitor.
    Moderate severityGrade 2 is moderate.
    Severe severityGrades 3-4 are severe.
    Covered acute courseCoverage is limited to infliximab 5 mg/kg for a maximum of 2 doses within 1 month; continuation is not a covered benefit.